> Research Use Only Disclaimer: Hexarelin has not been approved by the FDA or any major regulatory agency for human therapeutic use. It is available only as a research chemical. This article summarizes publicly available scientific literature for educational and research purposes only. Not for human use.
---
What Is Hexarelin?
Hexarelin is a synthetic hexapeptide growth hormone secretagogue with the sequence His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂, differing from GHRP-6 by a single key modification: the D-Trp at position 2 is replaced by D-2-methyltryptophan (D-2-MeTrp). This seemingly minor structural change produces a compound with substantially greater GHS-R1a affinity and GH-releasing potency than any other GHRP, earning hexarelin its designation as the most potent synthetic GHRP characterized to date.
Hexarelin was developed at Europeptides (Rome, Italy) in the early 1990s as a structural analog of GHRP-6, aiming to optimize receptor affinity through targeted methylation of the D-Trp residue. The compound attracted immediate research interest for two reasons:
1. Exceptional GH-releasing potency — greater than GHRP-6, GHRP-2, or ipamorelin in comparative dose-response studies
2. Unique cardiac biology — subsequent research revealed that hexarelin binds cardiac-specific receptors and produces GH-independent cardioprotective effects, a property not shared by other GHRPs
These dual aspects make hexarelin one of the most scientifically complex and research-rich compounds in the GHRP class.
---
Mechanism of Action at the Pituitary: GHS-R1a Agonism
Receptor Binding and Potency
Hexarelin is a full agonist at GHS-R1a, the canonical ghrelin receptor, with binding affinity (Ki) approximately 3–10-fold higher than GHRP-6 in competitive binding assays. This enhanced affinity results from the D-2-MeTrp modification, which provides additional hydrophobic contacts with the receptor's transmembrane binding pocket.
The signal transduction cascade follows the standard GHS-R1a pathway:
1. Gαq activation → phospholipase C-β → IP₃ + DAG
2. IP₃-mediated Ca²⁺ release from endoplasmic reticulum
3. DAG-activated PKC
4. Combined calcium surge and PKC activation → GH secretory granule exocytosis
GH Release Potency in Comparative Studies
In head-to-head studies:
- •Hexarelin produces 2–5× greater GH area under the curve (AUC) than GHRP-6 at equivalent molar doses
- •Hexarelin produces 1.5–3× greater GH AUC than GHRP-2
- •The GH response to hexarelin is dose-dependent up to ~2 μg/kg IV, after which additional doses produce diminishing returns (suggesting receptor saturation)
Desensitization — The Key Limitation
The same high affinity that makes hexarelin the most potent GHRP also produces the most pronounced receptor downregulation (tachyphylaxis) with repeated dosing. Studies have demonstrated:
- •Repeated hexarelin dosing at intervals <6 hours produces substantially attenuated GH responses vs. the first dose
- •After several days of continuous administration, GH response blunting of 40–70% has been documented
- •Receptor recovery after hexarelin discontinuation requires longer periods than with GHRP-2 or GHRP-6
This desensitization profile is a critical design consideration for hexarelin research protocols. Most investigators use intermittent dosing schedules with extended inter-dose intervals (≥6–12 hours) and regular off-cycle periods.
---
Cardiac Biology: GH-Independent Cardioprotection
Hexarelin's most scientifically distinctive property is its cardiac-specific receptor binding and GH-independent cardioprotective effects — a feature unique among GHRPs that has generated substantial research interest independent of the GH axis.
The Cardiac GHS Receptor Is Not GHS-R1a
Research from multiple groups established that the cardiac binding site for hexarelin is pharmacologically distinct from the pituitary GHS-R1a:
- •Peptidyl GHSs (hexarelin, Tyr-Ala-hexarelin, EP80317) bind with high affinity to cardiac tissue
- •Non-peptidyl GHSs (MK-0677, which binds GHS-R1a with high affinity at the pituitary) show very low cardiac binding
- •This pharmacological distinction confirms a separate cardiac receptor that preferentially recognizes peptidyl GHS structures
Research by Bodart et al. (Circ Res 1999) characterized this cardiac GHS receptor as an alternative subtype. Subsequent work identified CD36 (scavenger receptor B2) as a mediator of some hexarelin cardiac effects — a lipid scavenger receptor that also functions as a signaling receptor for peptidyl GHSs in cardiac tissue.
GH-Independent Cardioprotection: Key Evidence
The most compelling evidence for GH-independent cardiac effects came from studies in hypophysectomized rats (animals with surgically removed pituitaries, unable to secrete GH):
- •Hexarelin treatment produced significant cardioprotection against ischemia-reperfusion injury in these GH-deficient animals
- •Normal GH levels were not restored by hexarelin in hypophysectomized rats (confirming the pituitary was absent)
- •Yet cardiac protection was indistinguishable from that seen in intact animals receiving hexarelin
- •GH replacement alone in hypophysectomized rats did NOT replicate the cardiac protection seen with hexarelin
This elegantly demonstrates that hexarelin's cardiac effects are primary cardiac actions mediated by myocardial receptors, not secondary consequences of elevated GH or IGF-1.
Specific Cardiac Research Findings
Hexarelin and ischemia-reperfusion injury (PMID 11322492):
A study examining hexarelin's role in calcium deprivation-replenishment injury in cardiac H9c2 cells demonstrated that hexarelin — but not GH — protected cells from Ca²⁺ overload-induced death. The protection was mediated by intracellular calcium regulation, preserving phospholamban phosphorylation and sarcoplasmic reticulum Ca²⁺ content during reperfusion stress.
Hexarelin and cardiac fibrosis (PMID 29756411):
In a mouse model of acute myocardial infarction, hexarelin treatment:
- •Preserved myocardial function (improved ejection fraction vs. vehicle)
- •Reduced cardiac fibrosis (lower collagen deposition in the infarct border zone)
- •Attenuated cardiomyocyte hypertrophy
These effects were associated with modulation of TGF-β/Smad signaling pathways in cardiac fibroblasts.
Hexarelin and cardiomyocyte proliferation (PMID 12379504):
Research demonstrated that both ghrelin and hexarelin stimulate H9c2 cardiomyocyte cell proliferation in vitro, suggesting a trophic role for GHS-R1a/cardiac GHS receptor activation in maintaining cardiac cell populations. This proliferative effect may contribute to the observed cardioprotection in myocardial infarction models.
The EP80317 Angle: Hexarelin's Selective Cardiac Analog
Researchers at Europeptides developed EP80317, an analog of hexarelin with high affinity for cardiac GHS receptors but reduced pituitary GHS-R1a activity. EP80317 studies provide a clean pharmacological separation of cardiac vs. GH-axis effects — confirming that the cardiac biology is receptor-mediated and mechanistically distinct from pituitary GH release.
---
GHRP Potency Hierarchy and Research Context
| GHRP | GH Potency | Cardiac Receptor | Appetite | Desensitization |
|---|---|---|---|---|
| Hexarelin | ★★★★★ (highest) | Strong (CD36/cardiac GHS-R) | Low-moderate | Fastest |
| GHRP-2 | ★★★★ | Weak | Moderate | Moderate |
| GHRP-6 | ★★★ | Weak | Strong | Moderate |
| Ipamorelin | ★★★ | Minimal | Minimal | Slowest |
For research specifically targeting maximum GH release in short-term studies, hexarelin is the obvious choice. For studies where desensitization must be minimized, ipamorelin or GHRP-2 are preferable. For cardiac receptor biology specifically, hexarelin (or EP80317) is the essential tool.
See: Hexarelin vs GHRP-6 comparison and GHRPs Compared full guide.
---
Key Research Studies
Bowers CY 1998 — GHRP Class Review (PMID 9893708)
The authoritative Bowers review placed hexarelin within the GHRP pharmacological hierarchy, documenting its superior GH-releasing potency vs. GHRP-6 and characterizing the dose-response relationships that established hexarelin as the benchmark for GHRP potency.
Hexarelin Cardioprotection — Ischemia/Reperfusion (PMID 11322492)
Demonstrated GH-independent cardiac protection via calcium homeostasis — the foundational study establishing hexarelin's cardiac pharmacology as a research domain distinct from GH axis biology.
Hexarelin, Cardiac Fibrosis and MI (PMID 29756411)
Showed improved cardiac function and reduced fibrosis after myocardial infarction in mice, with mechanistic links to TGF-β/Smad pathway modulation. Represents the current frontier of hexarelin cardiac research.
Cardiomyocyte Proliferation Studies (PMID 12379504)
Natural (ghrelin) and synthetic (hexarelin) GHS stimulate H9c2 cardiomyocyte cell proliferation — supporting a trophic cardiac role for GHS peptides beyond acute cardioprotection.
Hexarelin Dosing and Desensitization Studies
Multiple groups documented dose-response desensitization kinetics with hexarelin, establishing the practical dosing constraints that govern its use in research protocols. See: Hexarelin dosage guide.
---
Research Applications
Hexarelin is uniquely positioned for:
- •Maximum GH release studies — when the research aim requires peak GH axis activation in a single administration
- •Cardiac receptor biology — the only GHRP with established, mechanistically characterized cardiac-specific receptor binding
- •Myocardial ischemia-reperfusion research — cardioprotection studies independent of GH axis manipulation
- •Cardiac fibrosis models — TGF-β pathway modulation via cardiac GHS receptors
- •GHS potency benchmarking — established reference point for comparing GHRP analogs
- •Tachyphylaxis studies — hexarelin's fast desensitization profile makes it an ideal model for studying GHS-R1a downregulation and recovery
---
Sourcing & Price Comparison (2026 Live Data)
Hexarelin commands a premium over GHRP-2 and GHRP-6 due to the D-2-MeTrp synthesis complexity and its established research demand in cardiac biology.
| Supplier | Price/mg | Product |
|---|---|---|
| Pure Peptides UK | $6.00/mg | Hexarelin 5 mg |
| Peptides Source | $7.00/mg | Hexarelin Acetate 10 mg |
| Ruo Bio | $7.60/mg | Hexarelin |
| Top Peptides | $7.80/mg | Hexarelin 5 mg |
| Raw Amino | $8.20/mg | Hexarelin |
| Core Peptides | $8.70/mg | CJC+Hexarelin blend |
> Live pricing: Peptides.SO Hexarelin peptide page. See also: Hexarelin dosage guide and Hexarelin vs GHRP-6 comparison.
---
Frequently Asked Questions
Q: Why is hexarelin the most potent GHRP?
A: The D-2-methyltryptophan (D-2-MeTrp) substitution at position 2 (vs. D-Trp in GHRP-6) adds a methyl group that provides additional hydrophobic contacts with GHS-R1a's binding pocket. This increases receptor affinity (lower Ki) and receptor occupancy at equivalent doses, translating directly to greater GH release per unit dose compared to all other synthetic GHRPs.
Q: What distinguishes hexarelin's cardiac effects from other GHRPs?
A: Hexarelin binds a cardiac-specific receptor that is pharmacologically distinct from the pituitary GHS-R1a. Evidence: non-peptidyl GHSs like MK-0677 bind GHS-R1a with high affinity but show minimal cardiac binding; hexarelin shows high cardiac binding. Studies in hypophysectomized rats confirmed cardiac protection without any GH elevation, proving the effects are GH-independent and directly receptor-mediated in cardiac tissue. CD36 has been identified as one mediator of these cardiac effects.
Q: How does hexarelin desensitization affect research protocols?
A: Hexarelin's high potency comes with faster GHS-R1a downregulation than lower-potency GHRPs. Repeated dosing within short intervals produces attenuated GH responses. Most research protocols using hexarelin for GH studies therefore employ less frequent dosing (1–2× daily maximum) with regular off-cycle periods. For cardiac research, desensitization at the cardiac receptor follows different kinetics than at the pituitary and is less characterized.
Q: Can hexarelin be combined with GHRH analogs?
A: Yes. Like all GHRPs, hexarelin produces synergistic GH release when combined with GHRH analogs (CJC-1295, sermorelin). The synergy mechanism is the same: hexarelin acts via GHS-R1a (Gαq) while GHRH analogs act via GHRHR (Gαs) — two complementary intracellular pathways in somatotrophs. The combination produces substantially greater GH release than either alone. However, for research protocols, the rapid desensitization issue with hexarelin remains a design consideration.
Q: What is EP80317 and how is it related to hexarelin?
A: EP80317 is a hexarelin analog (Trp-Ala-Hexarelin derivative) developed specifically to study cardiac effects with reduced pituitary GH activity. EP80317 retains high affinity for the cardiac GHS receptor but has substantially reduced GHS-R1a activity at the pituitary, allowing researchers to selectively activate cardiac GHS receptors without concomitant GH elevation. It's a pharmacological tool for dissecting hexarelin's cardiac mechanism from its GH-axis mechanism.
Q: Is hexarelin relevant to atherosclerosis research?
A: Yes. CD36 (one of hexarelin's cardiac receptor mediators) is also expressed on macrophages and plays roles in foam cell formation and oxidized LDL uptake in atherosclerotic plaques. Hexarelin binding to CD36 has been investigated in contexts beyond cardiac muscle, including vascular biology and lipid metabolism research. This represents an emerging research frontier distinct from the GH or cardioprotection studies.
---
Disclaimer
This article is for educational and research informational purposes only. Hexarelin has not been approved by any major regulatory agency for human therapeutic use. All information reflects published scientific literature and does not constitute medical advice. Researchers should comply with all applicable regulations in their jurisdiction. For Research Use Only — Not for Human Consumption.
---
Related articles: GHRP-2 Research Profile 2026 · GHRP-6 Research Profile 2026 · GHRPs Compared full guide · Hexarelin dosage guide